Gujarat Themis Peer Comparison

NSE: GUJTHEM | BSE: 506879

₹411.05

₹-1.15 (-0.28%)

As on 28-Aug-2026IST

Market cap

₹5,346 Cr

Revenue (TTM)

₹174 Cr

P/E Ratio

109.8

P/B Ratio

Div. Yield

0.2 %

Edit

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	5,346	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	174	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	48.69	1,018.97	497.77	603.02	270.18
Net Margin (%)	27.66	10.47	20.72	22.63	23.29
RoE (%)	17.63	21.30	28.49	19.61	14.45
Price to Earnings	109.80	35.10	59.86	27.51	56.31
Price-To-Book	14.98	6.77	14.74	4.76	7.48

Income Statement (₹ Cr)

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	173.74	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	176.03	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	91.34	7,739.53	1,608.91	1,753.71	720.01
EBITDA	82.40	1,943.92	762.90	836.69	388.38
Depreciation	14.86	425.10	98.11	78.88	74.78
EBIT	67.55	1,518.82	664.79	757.81	313.60
Interest	4.69	148.45	26.33	5.43	0.26
Other Income	2.29	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	65.14	1,389.91	669.26	800.55	361.56
Provision for Tax	16.45	370.94	171.48	197.53	91.39
Profit after Tax	48.69	1,018.97	497.77	603.02	270.18

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	287.77	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	136.51	723.57	345.47	142.73	50.51
Current Liabilities	79.15	3,912.24	710.20	508.04	169.08
Total Liabilities	318.01	8,121.73	2,179.88	3,753.59	2,034.25

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	408.90	3,392.16	1,290.62	1,321.38	957.22
Current Assets	88.78	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	318.01	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	29.89	731.70	136.01	0.00	0.38
Net Current Assets	9.64	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	4.71	393.94	8.97	4.82	3.91

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	91.03	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-111.82	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	26.01	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	5.22	-56.25	44.21	-230.35	-14.24

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	27.48	22.49	23.45	25.50	29.62
ROE (%)	17.63	21.30	28.49	19.61	14.45
ROA (%)	12.10	11.42	19.48	16.31	12.66
EBIT Margin (%)	38.88	15.68	28.03	29.25	28.29
Net Margin (%)	27.66	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	17.51	18.36	78.33	7.93	-6.72
EBIT Growth (%)	16.55	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	9.17	32.39	182.61	21.66	-24.38
EPS Growth (%)	9.17	36.68	277.72	25.42	-21.99
Book Value Growth (%)	23.34	50.94	18.89	20.94	18.74

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	91.93	34.38	59.86	26.64	55.82
Price / Book Value	14.98	6.77	14.74	4.76	7.48
Dividend Yield (%)	0.16	0.19	0.15	0.37	0.51
EV/EBITDA	65.09	18.80	38.85	18.89	38.86
Market Cap (₹ Cr)	3,067.36	20,327.45	15,494.53	13,228.83	17,537.35

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.45	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.11	--	--	0.00
Current Ratio	1.12	1.43	2.09	5.21	7.39
Quick Ratio	0.93	0.82	1.37	3.85	5.46
Interest Coverage	14.88	10.36	26.41	148.49	1,386.30

	Gujarat Themis	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	35.06	26.46	22.82	41.42	41.52
Asset Turnover	0.43	1.09	0.93	0.70	0.52
Receivable days	70.51	87.83	85.17	132.12	132.49
Inventory Days	10.13	78.64	90.97	102.08	68.07
Payable days	193.03	174.97	137.94	133.54	123.94
Cash Conversion Cycle	-112.39	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.